House dust mite allergy immunotherapy - DBV Technologies

Drug Profile

House dust mite allergy immunotherapy - DBV Technologies

Alternative Names: Viaskin® HDM; Viaskin® House Dust Mite

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DBV Technologies
  • Developer DBV Technologies; Genclis
  • Class Allergens; Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hypersensitivity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Allergy in France (Topical, Patch)
  • 15 Nov 2012 Early research in Hypersensitivity (house dust mite allergy) in France (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top